C.R. Bard Inc. (NYSE:BCR) VP Betty D. Larson sold 4,032 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $225.33, for a total value of $908,530.56. Following the sale, the vice president now owns 10,298 shares of the company’s stock, valued at $2,320,448.34. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of C.R. Bard Inc. (NYSE:BCR) opened at 227.96 on Wednesday. The company’s 50 day moving average price is $220.20 and its 200 day moving average price is $217.61. C.R. Bard Inc. has a 12 month low of $172.21 and a 12 month high of $239.43. The company has a market cap of $16.74 billion, a price-to-earnings ratio of 53.01 and a beta of 0.57.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Tuesday, July 26th. The company reported $2.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.47 by $0.07. C.R. Bard had a return on equity of 48.43% and a net margin of 9.20%. The firm earned $931.50 million during the quarter, compared to analyst estimates of $915.22 million. During the same quarter in the previous year, the company posted $2.27 earnings per share. The company’s revenue was up 8.3% compared to the same quarter last year. On average, equities analysts expect that C.R. Bard Inc. will post $10.17 EPS for the current fiscal year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/c-r-bard-inc-bcr-vp-betty-d-larson-sells-4032-shares.html

BCR has been the subject of a number of recent analyst reports. Barclays PLC upped their target price on C.R. Bard from $212.00 to $224.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 24th. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Tuesday, May 24th. Piper Jaffray Cos. reiterated a “buy” rating and set a $241.00 target price on shares of C.R. Bard in a research report on Tuesday, May 24th. Leerink Swann reiterated a “hold” rating on shares of C.R. Bard in a research report on Wednesday, May 25th. Finally, Bank of America Corp. downgraded C.R. Bard from a “buy” rating to a “neutral” rating in a research report on Friday, July 8th. Thirteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $233.00.

A number of large investors have recently modified their holdings of the company. Fundsmith LLP increased its position in C.R. Bard by 24.7% in the second quarter. Fundsmith LLP now owns 2,197,626 shares of the company’s stock valued at $516,220,000 after buying an additional 435,595 shares in the last quarter. Panagora Asset Management Inc. increased its position in C.R. Bard by 3.5% in the first quarter. Panagora Asset Management Inc. now owns 499,651 shares of the company’s stock valued at $101,264,000 after buying an additional 17,012 shares in the last quarter. Squarepoint Ops LLC increased its position in C.R. Bard by 49.4% in the first quarter. Squarepoint Ops LLC now owns 5,152 shares of the company’s stock valued at $1,044,000 after buying an additional 1,703 shares in the last quarter. Silvercrest Asset Management Group LLC increased its position in C.R. Bard by 30.3% in the first quarter. Silvercrest Asset Management Group LLC now owns 6,026 shares of the company’s stock valued at $1,221,000 after buying an additional 1,401 shares in the last quarter. Finally, Societe Generale bought a new position in C.R. Bard during the second quarter valued at approximately $2,217,000. 87.90% of the stock is owned by hedge funds and other institutional investors.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.